Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
18
03
2022
accepted:
10
06
2022
pubmed:
25
6
2022
medline:
15
10
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children.
OBJECTIVES
OBJECTIVE
The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments.
METHODS
METHODS
We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms.
RESULTS
RESULTS
One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01).
DISCUSSION
CONCLUSIONS
Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.
Identifiants
pubmed: 35748102
doi: 10.1111/jdv.18361
pmc: PMC9349726
doi:
Substances chimiques
Biological Factors
0
Biological Products
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2076-2086Subventions
Organisme : Medical Research Council
ID : MR/T02383X/1
Pays : United Kingdom
Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Minozzi S, Bonovas S, Lytras T et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 2016; 15(Supp 1): 11-34.
Williamson EJ, Walker AJ, Bhaskaran K et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436.
Tsankov BK, Allaire JM, Irvine MA et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis 2021; 103: 246-256.
Izadi Z, Brenner EJ, Mahil SK et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 2021; 4: e2129639.
Mahil SK, Dand N, Mason KJ et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 2021; 147: 60-71.
FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE Consortium and Contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; 80: 527-538.
Fougerousse AC, Perrussel M, Bécherel PA et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. J Eur Acad Dermatol Venereol 2020; 34: e676-e679.
Gelfand JM, Armstrong AW, Bell S et al. National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 2021; 84: 1254-1268.
Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128: 39-42.
Naldi L, Peli L, Parazzini F, Carrel CF. Psoriasis study Group of the Italian Group for epidemiological research in dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001; 44: 433-438.
Seetharam KA, Sridevi K, Vidyasagar P. Cutaneous manifestations of chikungunya fever. Indian Pediatr 2012; 49: 51-53.
Beytout Q, Pepiot J, Maruani A et al. Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol 2021; 148: 106-111.
Bozonnat A, Assan F, LeGoff J, Bourrat E, Bachelez H. SARS-CoV-2 infection inducing severe flare up of deficiency of interleukin thirty-six (IL-36) receptor antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist. J Clin Immunol 2021; 41: 1511-1514.
Sigha OB, Kouotou EA. Infection à COVID-19 révélée par une poussée de psoriasis chez un Camerounais âgé: à propos d'un cas. Our Dermatol Online 2021; 12(Supp 1): 16-20.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243.
Mahé E, Maccari F, Ruer-Mulard M et al. Psoriasis de l'enfant vu en milieu libéral: les aspects cliniques et épidémiologiques diffèrent des données habituellement publiées. Ann Dermatol Venereol 2019; 146: 354-362.
Piaserico S, Gisondi P, Cazzaniga S, Di Leo S, Naldi L. Assessing the risk and outcome of COVID-19 in patients with psoriasis or psoriatic arthritis on biologic treatment: a critical appraisal of the quality of the published evidence. J Invest Dermatol 2022; 142: 355-363.
Naldi L, Cazzaniga S. More on Covid-19 in immune-mediated inflammatory diseases. N Engl J Med 2020; 383: 795-796.
FIMARAD. Recommandations. Patients atteints de maladies dermatologiques rares et Coronavirus. https://fimarad.org/wp-content/uploads/2020/03/Recommandations-CORONAVIRUS-FIMARAD-VF.pdf?utmsource=mailpoet&utmmedium=email&utmcampaign=recommandations-et-informations-covid-19-maladies-dermatologiques-rares98.
Mahil SK, Yates M, Yiu ZZN et al. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol 2021; 35: e636-e640.
Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol 2022; 186: 59-68.
Del Valle DM, Kim-Schulze S, Huang HH et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26: 1636-1343.
Castagnoli R, Votto M, Licari A et al. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr 2020; 174: 882-889.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020; 109: 1088-1095.
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-666.
Paller AS, Mercy K, Kwasny MJ et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol 2013; 149: 166-176.
Mahé E, Beauchet A, Bodemer C et al. Psoriasis and obesity in French children: a case-control, multicentre study. Br J Dermatol 2015; 172: 1593-1600.
Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr 2021; 180: 2019-2034.
Bautista-Rodriguez C, Sanchez-de-Toledo J, Clark BC et al. Multisystem inflammatory syndrome in children: an international survey. Pediatrics 2021; 147: e2020024554.
Wanga V, Gerdes ME, Shi DS et al. Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19 - six hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1766-1772.
Sbidian E, Madrange M, Viguier M et al. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol 2019; 181: 1304-1306.
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci 2019; 20: 4347.